Search results for Ontamalimab ELISA Kit
Ontamalimab ELISA Kit, ProteoGenix, KPTX248
Description of Ontamalimab ELISA Kit Introduction Ontamalimab, also known as Santolimab, is a human monoclonal antibody that targets the inflammatory cytokine interleukin-23 (IL-23). It is currently being developed as a potential therapy for autoimmune diseases such as Crohn’s disease and ulcerative colitis. In order to accurately measure the levels of ontamalimab in patient samples, an enzyme-linked immunosorbent assay (ELISA) kit has been developed. This article will provide a scientific description of the Ontamalimab ELISA Kit, including its structure, activity, and application. Structure of Ontamalimab ELISA Kit The Ontamalimab ELISA Kit consists of a 96-well microplate coated with a specific anti-ontamalimab antibody. This antibody is immobilized on the surface of the microplate and serves as the capture antibody. The kit also includes a biotinylated detection antibody, which binds to ontamalimab in the sample. This detection antibody is then detected by a streptavidin-HRP conjugate, which produces a colorimetric signal in the presence of a substrate. The intensity of this signal is directly proportional to the amount of ontamalimab present in the sample. Activity of Ontamalimab ELISA Kit The Ontamalimab ELISA Kit is a highly sensitive and specific method for quantifying the levels of ontamalimab in patient samples. The kit has a detection limit of 1 ng/mL and a dynamic range of 2-100 ng/mL. This allows for accurate measurement of ontamalimab levels in both low and high concentration samples. The kit also has a high inter- and intra-assay precision, with coefficients of variation of less than 10%. Application of Ontamalimab ELISA Kit The Ontamalimab ELISA Kit has a wide range of applications in both research and clinical settings. In research, the kit can be used to measure the pharmacokinetics of ontamalimab, as well as to monitor the levels of ontamalimab in preclinical and clinical studies. In clinical settings, the kit can be used to monitor the response to ontamalimab therapy in patients with autoimmune diseases. By measuring the levels of ontamalimab in patient samples, clinicians can assess the effectiveness of the therapy and make necessary adjustments to the treatment plan. Conclusion In conclusion, the Ontamalimab ELISA Kit is a valuable tool for accurately measuring the levels of ontamalimab in patient samples. Its high sensitivity, specificity, and precision make it a reliable method for monitoring ontamalimab therapy in patients with autoimmune diseases. As ontamalimab continues to be developed as a potential therapeutic option for various autoimmune diseases, the Ontamalimab ELISA Kit will play a crucial role in its clinical and research applications.
Host
Reactivity
Applications
Conjugation
Ontamalimab ELISA Kit, Abbexa, abx395137
Ontamalimab ELISA Kit is a quantitative ELISA kit for detection of Ontamalimab.Ontamalimab (SHP647) is a fully human, immunoglobulin G2 , antihuman mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody being developed for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). A population pharmacokinetic/pharmacodynamic (PK/PD) analysis was conducted using clinical phase 2 study data to evaluate the PK and PD of ontamalimab following subcutaneous administrations of 7.5, 22.5, 75, and 225 mg every 4 weeks in patients with moderate to severe UC or CD. A total of 440 patients with UC (n = 249; 56.6%) or CD (n = 191; 43.4%) were included in the analysis. A 2-compartment model with parallel linear and nonlinear elimination adequately characterized concentration-time profiles of ontamalimab. The apparent clearance and volume of distribution were 0.0127 L/h (0.305 L/day) and 6.53 L, respectively. Apparent clearance and volume of distribution were mainly dependent on baseline albumin and body weight, respectively. No differences in the PK properties of ontamalimab were observed between patients with UC or CD. The presence of antidrug antibodies did not impact the PK of ontamalimab. Nonlinear elimination occurred at very low concentrations and was unlikely to contribute to the elimination half-life under steady-state conditions. A linear PK/PD model described the relationship between ontamalimab and free MAdCAM-1. Minimum concentrations of ontamalimab at steady state following 75 mg every 4 weeks were associated with >95% suppression of circulating free MAdCAM-1. The PK/PD properties characterized support phase 3 testing in UC and CD.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.